Efalizumab( —— )

Catalog No. M36773 CAS No. 214745-43-4

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Efalizumab
Note

Research use only, not for human use.
Brief Description

Efalizumab, a novel potent regulator of T cells, is a humanized LFA-1 α subunit (CD11a) monoclonal antibody.
Description

Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research.
In Vitro

Efalizumab (78 ng/mL-5 mg/mL) induces a leukocytosis and downregulates LFA-1 expression on T cells in the peripheral blood.Efalizumab (78 ng/mL-5 mg/mL) downregulates plate-bound, anti-CD3-stimulated proliferation of PBMC.
In Vivo

Efalizumab shows side effects include bacterial sepsis, viral meningitis, invasive fungal disease and progressive multifocal leukoencephalopathy (PML), a brain infection caused by reactivation of latent JC virus infection.
Synonyms

——
Pathway

Cell Cycle/DNA Damage
Target

Integrin
Recptor

Integrin
Research Area

——
Indication

——

1. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S98-104. ?

Calculator

molnova catalog